Literature DB >> 3926225

Malignant hypercalcaemia.

J C Stevenson.   

Abstract

Entities:  

Mesh：

Year:  1985        PMID： 3926225      PMCID： PMC1416311          DOI： 10.1136/bmj.291.6493.421

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  21 in total

1.  Evidence for the secretion of an osteoclast stimulating factor in myeloma.

Authors:  G R Mundy; L G Raisz; R A Cooper; G P Schechter; S E Salmon
Journal:  N Engl J Med       Date:  1974-11-14       Impact factor: 91.245

2.  Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease.

Authors:  N C Thalassinos; G F Joplin
Journal:  Lancet       Date:  1970-09-12       Impact factor: 79.321

3.  Salmon calcitonin in the treatment of hypercalcemia.

Authors:  O L Silva; K L Becker
Journal:  Arch Intern Med       Date:  1973-09

4.  Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.

Authors:  M L Binstock; G R Mundy
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

5.  Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.

Authors:  M C Chapuy; P J Meunier; C M Alexandre; E P Vignon
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

6.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

7.  Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy.

Authors:  G R Mundy; M E Rick; R Turcotte; M A Kowalski
Journal:  Am J Med       Date:  1978-10       Impact factor: 4.965

8.  Prostaglandins and breast cancer.

Authors:  A Bennett; E M Charlier; A M McDonald; J S Simpson; I F Stamford; T Zebro
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

9.  Hypercalcaemia--a hospital survey.

Authors:  R A Fisken; D A Heath; A M Bold
Journal:  Q J Med       Date:  1980

10.  Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E 2 . A new model for the hypercalcemia of cancer.

Authors:  A H Tashjian; E F Voelkel; L Levine; P Goldhaber
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307
View more
  3 in total

1.  Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.

Authors:  S H Ralston; A A Alzaid; M D Gardner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

2.  Parathyroid hormone like bioactivity measured by cytochemical bioassay in a patient with malignant bladder disease.

Authors:  S Roche; J F Fielding; N Loveridge
Journal:  Ir J Med Sci       Date:  1988-12       Impact factor: 1.568

Review 3.  Current management of malignant hypercalcaemia.

Authors:  J C Stevenson
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.